Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study

AIDS Patient Care and STDs

Volumn 23, Issue 8, 2009, Pages 589-592

  Young, Benjamin ^a,b   Buchacz, Kate ^c   Moorman, Anne ^c   Wood, Kathy C ^d   Brooks, John T ^c  

^a Denver Infectious Disease Consultants   (United States)

^b Health Connections International   (Netherlands)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CERNER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; OUTPATIENT CARE;

ADENINE; ADULT; AGED; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; UNITED STATES;

EID: 70350167816     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0232     Document Type: Article

References (21)

1. Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: A tale of two races. J Infect Dis 2008;197:1548-1557.
2. Winston J, Deray G, Hawkins T, et al. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008;47:1449-1457.
3. Fine DM, Atta MG. Kidney disease in the HIV-infected patient. AIDS Patient Care STDs 2007;21:813-824.
4. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-1585.
5. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. November 3, 2008. www .aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Last accessed June 2, 2009).
6. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-1263.
7. Squires K, Pozniak AL, Pierone G Jr., et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med 2003;139:313-320.
8. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviralnaive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005;20:743-746.
9. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201.
10. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
11. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004;35:269-273.
12. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18:1074-1076.
13. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovirassociated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 2006;42:283-290.
14. Gupta SK. Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system. AIDS Patient Care STDs 2008;22:99-103.
15. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: A retrospective cohort study. HIV Med 2005;6:284-290.
16. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-1198.
17. Winston A, Amin J, Mallon PW, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with Tenofovir DF containing highly active antiretroviral theraphy. HIV Med 2006;7:105-111.
18. Moreno S, Domingo P, Palacios R, et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: Data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr 2006;42:385-387.
19. Young B, Buchacz K, Baker RK, et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:178-187.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
21. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.